CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 23412-23651
Annnotations
CORD-19-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T245 | 0-239 | Sentence | denotes | In patients with documented HAHA and/or IgE-mediated reactions to trastuzumab and clinical symptoms of type I/mast cell mediator-related symptoms, desensitization can allow continued administration of this treatment by providing tolerance. |
Epistemic_Statements
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32 | 0-239 | Epistemic_statement | denotes | In patients with documented HAHA and/or IgE-mediated reactions to trastuzumab and clinical symptoms of type I/mast cell mediator-related symptoms, desensitization can allow continued administration of this treatment by providing tolerance. |
CORD-19_Custom_license_subset
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T245 | 0-239 | Sentence | denotes | In patients with documented HAHA and/or IgE-mediated reactions to trastuzumab and clinical symptoms of type I/mast cell mediator-related symptoms, desensitization can allow continued administration of this treatment by providing tolerance. |